Telomir Pharmaceuticals announces BIO 2025 participation and preclinical progress for Telomir-1

Telomir Pharmaceuticals, Inc.

Telomir will participate in the BIO International Convention 2025 in Boston from June 16-19, 2025, with scheduled partnering meetings.
The company plans to submit an IND by year-end and initiate first-in-human clinical trials in the first half of 2026.
Preclinical data showed retinal regeneration in AMD, lifespan extension in Progeria/Werner's, reversal of Type 2 diabetes parameters, and ~50% tumor reduction in prostate cancer model.
Telomir launched a rare disease initiative targeting Werner's, Wilson's, Progeria, and dysphonia, and introduced Telomir-Ag2 for multidrug-resistant bacteria including MRSA.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.